V Square Quantitative Management LLC Buys 132 Shares of Illumina, Inc. (NASDAQ:ILMN)

V Square Quantitative Management LLC raised its stake in Illumina, Inc. (NASDAQ:ILMN) by 50.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 393 shares of the life sciences company’s stock after acquiring an additional 132 shares during the quarter. V Square Quantitative Management LLC’s holdings in Illumina were worth $52,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. WCM Investment Management LLC increased its holdings in shares of Illumina by 26.6% during the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after purchasing an additional 867,673 shares during the period. Geode Capital Management LLC boosted its position in Illumina by 1.8% in the third quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock valued at $354,933,000 after buying an additional 48,018 shares in the last quarter. Primecap Management Co. CA boosted its position in Illumina by 3.6% in the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock valued at $328,158,000 after buying an additional 87,599 shares in the last quarter. Janus Henderson Group PLC boosted its position in Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after buying an additional 625,245 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Illumina by 4.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock valued at $164,334,000 after buying an additional 54,319 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ILMN. Barclays lowered shares of Illumina from an “equal weight” rating to an “underweight” rating and cut their price target for the stock from $130.00 to $100.00 in a report on Monday, February 10th. Morgan Stanley lowered their target price on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 11th. Canaccord Genuity Group lowered their target price on shares of Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Friday, February 7th. Citigroup downgraded shares of Illumina from a “buy” rating to a “neutral” rating and decreased their price target for the company from $190.00 to $165.00 in a research note on Wednesday, December 11th. Finally, TD Cowen downgraded shares of Illumina from a “buy” rating to a “hold” rating and decreased their price target for the company from $177.00 to $140.00 in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Illumina presently has a consensus rating of “Moderate Buy” and a consensus target price of $159.45.

Illumina Stock Down 1.5 %

ILMN opened at $100.24 on Tuesday. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The stock has a market cap of $15.90 billion, a price-to-earnings ratio of -13.05 and a beta of 1.10. Illumina, Inc. has a twelve month low of $99.35 and a twelve month high of $156.66. The company’s 50-day moving average price is $132.74 and its two-hundred day moving average price is $134.91.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. As a group, equities analysts expect that Illumina, Inc. will post 4.42 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.